Phase 1/2 study of spevatamig (PT886) in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).Anwaar Saeed, Harshabad Singh, Jason T. Henry et al.|Journal of Clinical Oncology|2026Cited by 2